沃华医药(002107) - 2018 Q1 - 季度财报

Revenue Performance - Revenue for the first quarter reached ¥185,240,304.65, an increase of 17.36% compared to ¥157,840,570.38 in the same period last year[8]. Profitability - Net profit attributable to shareholders was ¥17,229,854.39, a decrease of 8.55% from ¥18,840,530.27 year-on-year[8]. - For the first half of 2018, the net profit attributable to shareholders of the listed company is expected to be positive, with a change range of 0.00% to 50.00%, translating to a net profit range of 35.91 million to 53.86 million yuan[21]. - The net profit for the first half of 2017 was 35.91 million yuan, indicating a potential increase in sales revenue as the reason for the expected profit growth[21]. Cash Flow - Net cash flow from operating activities was ¥15,696,505.27, down 55.82% from ¥35,524,549.32 in the previous year[8]. - Net cash flow from operating activities decreased by 19.83 million yuan, a reduction of 55.82% compared to the same period last year, primarily due to an increase in operating cash expenditures exceeding the increase in cash income[18]. - Net cash flow from investing activities decreased by 3.79 million yuan, a reduction of 101.74% compared to the same period last year, mainly due to increased fixed asset investments[18]. Asset Management - Total assets at the end of the reporting period were ¥888,830,706.75, reflecting a 3.90% increase from ¥855,495,508.77 at the end of the previous year[8]. - Other receivables increased by 91.72% to ¥35,746,700.00, primarily due to an increase in marketing reserve funds[15]. - Inventory rose by 34.79% to ¥76,619,900.00, attributed to an increase in stock of goods[16]. - Prepaid expenses surged by 808.75% to ¥3,546,500.00, mainly due to increased advance payments for materials[16]. Expense Management - Sales expenses increased by 32.74% to ¥109,673,000.00, driven by enhanced marketing efforts for key products[17]. - Cash paid for purchasing goods and services rose by 143.62% to ¥37,196,700.00, reflecting higher payments for raw material procurement[17]. Return on Equity - The weighted average return on equity decreased to 3.09% from 3.78% year-on-year[8].